RTX-117 is an investigational small molecule designed to modulate the Integrated Stress Response (ISR) pathway, with the goal of restoring protein translation homeostasis implicated in Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM) ReviR has dosed the first participant in a Phase 1 trial of RTX-117, initially evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy participants Milestone marks the clinical entry of a potential first-in-class therapy for CMT and VWM co-discovered using XtalPi's AI and robotics drug R&D platform CAMBRIDGE, Mass. & SHANGHAI, March 2, 2026 /PRNewswire/ -- XtalPi, a global leading AI- and robotics-driven drug discovery platform, today noted a key milestone in its collaboration with ReviR Therapeutics: dosing of the first participant in the Phase 1 clinical trial of RTX-117, an investigational small molecule being developed for Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM).